A non-government resource for the Medicare community
Powered by Q1Group LLC
A non-government Medicare community resource

May 2018 summary of the new medications added to Medicare Part D plan formularies (drug lists)

Category: Monthly Formulary Changes
Published: May, 31 2018 12:05:39

The May, 2018 Medicare Part D plan formulary data (or drug lists) includes the addition of 63 new National Drug Codes (NDC) to the Medicare Part D program.  These NDCs represent 43 different drugs, many with multiple strengths. Three new generic equivalents were added, Atazanavir Sulfate, the generic for Reyataz®, Doripenem, the generic for Doribax®, Tenofovir Disoproxil Fumarate, the generic for Viread®, along with a few new strengths and or manufactures for Niacin ER [Niaspan ER®] and Tolterodine Tartrate [Detrol LA®].
In addition, Eight new brand-name drugs, some with multiple strengths, were added to Medicare Part D plan formularies.  These drugs include, ALTAVERA-28®, CINVANTI®, EMFLAZA®, ENSKYCE®, KURVELO®, SEEBRI NEOHALER®, SHINGRIX®, and UTIBRON NEOHALER®.

The NDC uniquely identifies a particular drug, manufacturer, strength, and packaging combination. The NDC is often shown on your prescription bottle as an 11-digit code (see the charts below) or could be formatted as 00000-0000-00 where the first set of numbers identifies the manufacturer, the second set of number identifies the product and strength, and the third set of numbers identifies the packaging.

There are many reasons for NDCs to be added to the Medicare Part D program, a summary for all 63 new NDCs is as follows:

Reason for NDC Addition Occurrences
New Delivery Form 1
New Delivery Form and Strength 5
New Drug 9
New Drug and Strength 7
New Manufacturer 8
New Manufacturer and Delivery Form 1
New Manufacturer and Strength 11
New Manufacturer, Strength and Delivery Form
New Packaging 1
New Product Code 1
New Quantity 1
New Strength 16
Total New NDCs 63

The following chart details the first 63 new manufacturer / drug-strength / packaging combinations (NDCs) that were added to one or more Medicare Part D formularies in the most recent updates. You can click on the Drug Code (NDC)  or Drug Name below to go to our Q1Medicare.com DrugFinder to see the details of how this drug is covered by all Medicare Part D Plans in Florida -- You can then change the state to your state for details in your service area.

NDC Drug Name Notes
75987011110 ACTIMMUNE 100 MCG/0.5 ML VIAL New Manufacturer
00781558315 ALTAVERA-28 TABLET New Drug
63020018030 ALUNBRIG 180 MG TABLET New Manufacturer and Strength
63020009007 ALUNBRIG 90 MG TABLET New Manufacturer and Strength
63020019830 ALUNBRIG 90 MG-180 MG TAB PACK New Manufacturer and Strength
51672405706 AMIODARONE HCL 400 MG TABLET New Strength
00093552606 ATAZANAVIR SULFATE 150 MG CAP [Reyataz] New Drug and Strength
00093552706 ATAZANAVIR SULFATE 200 MG CAP [Reyataz] New Drug and Strength
00093552856 ATAZANAVIR SULFATE 300 MG CAP [Reyataz] New Drug and Strength
59385002660 BELBUCA 750 MCG FILM New Strength
57664066383 CARVEDILOL ER 10 MG CAPSULE New Strength
57664066483 CARVEDILOL ER 20 MG CAPSULE New Strength
57664066583 CARVEDILOL ER 40 MG CAPSULE New Strength
47426020101 CINVANTI 130 MG/18 ML VIAL New Drug
60505616100 DORIPENEM 500 MG VIAL [Doribax] New Drug
00003376474 ELIQUIS 5 MG STARTER PACK New Packaging
42998050203 EMFLAZA 18 MG TABLET New Drug and Strength
42998050521 EMFLAZA 22.75 MG/ML ORAL SUSP New Drug, Delivery Form and Strength
42998050303 EMFLAZA 30 MG TABLET New Drug and Strength
42998050403 EMFLAZA 36 MG TABLET New Drug and Strength
42998050101 EMFLAZA 6 MG TABLET New Drug and Strength
68180088213 ENSKYCE 28 TABLET New Drug
00378877035 ESTRADIOL 0.01% CREAM New Delivery Form
16714050402 GABAPENTIN 300 MG CAPSULE New Manufacturer and Strength
50242013201 HERCEPTIN 150 MG VIAL New Strength
54766059010 IMURAN 50 MG TABLET New Manufacturer
00574200216 KIONEX 15 GM/60 ML SUSPENSION New Strength
68180084413 KURVELO TABLET New Drug
70515026010 LANOXIN 500 MCG/2 ML AMPULE New Manufacturer and Strength
00378655053 LEVONOR-ETH ESTRAD 0.15-0.03 New Quantity
70257056001 LIORESAL IT 10 MG/20 ML KIT AMPUL New Manufacturer
70257056102 LIORESAL IT 10 MG/5 ML KIT AMPUL New Manufacturer
00071102701 LYRICA CR 165 MG TABLET ER 24H New Strength
00071102901 LYRICA CR 330 MG TABLET ER 24H New Strength
00071102601 LYRICA CR 82.5 MG TABLET ER 24H New Strength
00548570100 MEDROXYPROGESTERONE 150 MG/ML New Manufacturer
47335061481 NIACIN ER 750 MG TABLET [Niaspan ER] New Manufacturer and Strength
00074326590 NIASPAN ER 500 MG TABLET New Strength
62559021031 NIMODIPINE 30 MG CAPSULE New Manufacturer
00597036055 PRADAXA 150 MG CAPSULE New Strength
00597035556 PRADAXA 75 MG CAPSULE New Strength
00088210224 PRIFTIN 150 MG TABLET New Product Code
69102020060 ROWEEPRA XR 500 MG TABLET ER 24H New Strength
69102020160 ROWEEPRA XR 750 MG TABLET ER 24H New Strength
00078066219 SEEBRI NEOHALER 15.6 MCG INHAL New Drug
49702023755 SELZENTRY 20 MG/ML ORAL SOLN New Strength and Delivery Form
58160081912 SHINGRIX VIAL KIT New Drug
00006536403 STEGLATRO 15 MG TABLET New Delivery Form and Strength
00006536303 STEGLATRO 5 MG TABLET New Delivery Form and Strength
00006536803 STEGLUJAN 15-100 MG TABLET New Delivery Form and Strength
00006536703 STEGLUJAN 5-100 MG TABLET New Delivery Form and Strength
00093710456 TENOFOVIR DISOP FUM 300 MG TB [Viread] New Drug
00093001006 TOLTERODINE TARTRATE 1 MG TAB [Detrol LA] New Manufacturer, Strength and Delivery Form
00093001805 TOLTERODINE TARTRATE 2 MG TAB [Detrol LA] New Manufacturer and Delivery Form
70347010002 TOPROL XL 100 MG TABLET ER 24H New Manufacturer and Strength
70347002502 TOPROL XL 25 MG TABLET ER 24H New Manufacturer and Strength
70347005002 TOPROL XL 50 MG TABLET ER 24H New Manufacturer and Strength
10019055303 TRANSDERM-SCOP 1.5 MG/3 DAY New Manufacturer
00078066419 UTIBRON NEOHALER 27.5-15.6 MCG New Drug
31722033401 WARFARIN SODIUM 7.5 MG TABLET New Manufacturer and Strength
00310622560 XIGDUO XR 2.5 MG-1,000 MG TABLET New Strength
00023611401 ZENPEP DR 40,000 UNIT CAPSULE New Manufacturer
00078067615 ZOFRAN 8 MG TABLET New Manufacturer and Strength

You can review any Medicare plan formulary using the Q1Medicare.com FormularyBrowser at FormularyBrowser.com or compare how any medication is covered on all Medicare plans in your service area using our Q1Rx.com.

Tips & Disclaimers
  • Q1Medicare®, Q1Rx®, and Q1Group® are registered Service Marks of Q1Group LLC and may not be used in any advertising, publicity, or for commercial purposes without the express authorization of Q1Group.
  • The Medicare Advantage and Medicare Part D prescription drug plan data on our site comes directly from Medicare and is subject to change.
  • Medicare has neither reviewed nor endorsed the information on our site.
  • We provide our Q1Medicare.com site for educational purposes and strive to present unbiased and accurate information. However, Q1Medicare is not intended as a substitute for your lawyer, doctor, healthcare provider, financial advisor, or pharmacist. For more information on your Medicare coverage, please be sure to seek legal, medical, pharmaceutical, or financial advice from a licensed professional or telephone Medicare at 1-800-633-4227.
  • We are an independent education, research, and technology company. We are not affiliated with any Medicare plan, plan carrier, healthcare provider, or insurance company. We are not compensated for Medicare plan enrollments. We do not sell leads or share your personal information.
  • Benefits, formulary, pharmacy network, provider network, premium and/or co-payments/co-insurance may change on January 1 of each year. Our PDPCompare.com and MACompare.com provide highlights of annual plan benefit changes.
  • The benefit information provided is a brief summary, not a complete description of benefits. For more information contact the plan.
  • Limitations, copayments, and restrictions may apply.
  • We make every effort to show all available Medicare Part D or Medicare Advantage plans in your service area. However, since our data is provided by Medicare, it is possible that this may not be a complete listing of plans available in your service area. For a complete listing please contact 1-800-MEDICARE (TTY users should call 1-877-486-2048), 24 hours a day/7 days a week or consult www.medicare.gov.
    Statement required by Medicare:
    "We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options."
  • When enrolling in a Medicare Advantage plan, you must continue to pay your Medicare Part B premium.
  • Medicare beneficiaries with higher incomes may be required to pay both a Medicare Part B and Medicare Part D Income Related Monthly Adjustment Amount (IRMAA). Read more on IRMAA.
  • Medicare Advantage plans that include prescription drug coverage (MAPDs) are considered Medicare Part D plans and members with higher incomes may be subject to the Medicare Part D Income Related Monthly Adjustment Amount (IRMAA), just as members in stand-alone Part D plans. In certain situations, you can appeal IRMAA.
  • You must be enrolled in both Medicare Part A and Part B to enroll in a Medicare Advantage plan. Members may enroll in a Medicare Advantage plan only during specific times of the year. Contact the Medicare plan for more information.
  • If you are enrolled in a Medicare plan with Part D prescription drug coverage, you may be eligible for financial Extra Help to assist with the payment of your prescription drug premiums and drug purchases. To see if you qualify for Extra Help, call: 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048, 24 hours a day/ 7 days a week or consult www.medicare.gov; the Social Security Office at 1-800-772-1213 between 7 a.m. and 7 p.m., Monday through Friday. TTY users should call, 1-800-325-0778; or your state Medicaid Office.
  • Medicare evaluates plans based on a 5-Star rating system. Star Ratings are calculated each year and may change from one year to the next.
  • A Medicare Advantage Private Fee-for-Service plan (PFFS) is not a Medicare supplement plan. Providers who do not contract with the plan are not required to see you except in an emergency.
  • Disclaimer for Institutional Special Needs Plan (SNP): This plan is available to anyone with Medicare who meets the Skilled Nursing Facility (SNF) level of care and resides in a nursing home.
  • Disclaimer for Dual Eligible (Medicare/Medicaid) Special Needs Plan (SNP): This plan is available to anyone who has both Medical Assistance from the State and Medicare. Premiums, co-pays, co-insurance, and deductibles may vary based on the level of Extra Help you receive. Please contact the plan for further details.
  • Disclaimer for Chronic Condition Special Needs Plan (SNP): This plan is available to anyone with Medicare who has been diagnosed with the plan specific Chronic Condition.
  • Medicare MSA Plans combine a high deductible Medicare Advantage Plan and a trust or custodial savings account (as defined and/or approved by the IRS). The plan deposits money from Medicare into the account. You can use this money to pay for your health care costs, but only Medicare-covered expenses count toward your deductible. The amount deposited is usually less than your deductible amount, so you generally have to pay out-of-pocket before your coverage begins.
  • Medicare MSA Plans do not cover prescription drugs. If you join a Medicare MSA Plan, you can also join any separate (stand-alone) Medicare Part D prescription drug plan
  • There are additional restrictions to join an MSA plan, and enrollment is generally for a full calendar year unless you meet certain exceptions. Those who disenroll during the calendar year will owe a portion of the account deposit back to the plan. Contact the plan provider for additional information.
  • Medicare beneficiaries may enroll through the CMS Medicare Online Enrollment Center located at www.medicare.gov.
  • Medicare beneficiaries can file a complaint with the Centers for Medicare & Medicaid Services by calling 1-800-MEDICARE 24 hours a day/7 days or using the medicare.gov site. Beneficiaries can appoint a representative by submitting CMS Form-1696.